Developing first-in-class cardiovascular biopharmaceuticals that target natural repair pathways.

Dermal Scar Prevention

Skin scarring is a significant problem effecting a large population. Both hypertrophic and keloid scarring are common and JVS-100 may provide an opportunity to reduce scarring following a number of cosmetic, reconstructive, and other surgical procedures. It is estimated that over 16 million surgical procedures are conducted in the US annually which may be suitable for JVS-100 use.

Clinical and preclinical studies have demonstrated JVS-100’s therapeutic potential for indications beyond cardiovascular disease. In hypertrophic scar and keloid animal models, it has been demonstrated that administration of JVS-100 to the skin immediately following the closure of a surgical incision accelerated the rate of wound healing and reduced scar formation. Based on these data, a 26-patient Phase 1b placebo-controlled, randomized, double-blinded clinical trial was performed to evaluate the safety and efficacy of dermal JVS-100 delivery to the edges of a sternal incision immediately following open-heart surgery. The study showed dose-dependent trends in improvements relative to placebo in scar volume and width, measured by three dimensional imaging, and in cosmetic outcomes as measured by both the patient and the observing physician using the Patient and Observer Scar Assessment Scale. We believe these results validate our potential to expand JVS-100’s application to indications outside of the cardiovascular field. A detailed synopsis of this clinical study in dermal scarring is available through the following link: